Great Lakes Advisors LLC Decreases Stock Holdings in Zoetis Inc (NYSE:ZTS)

Great Lakes Advisors LLC decreased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,085 shares of the company’s stock after selling 1,656 shares during the period. Great Lakes Advisors LLC’s holdings in Zoetis were worth $8,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Glassman Wealth Services raised its stake in Zoetis by 306.5% in the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock valued at $25,000 after purchasing an additional 190 shares during the last quarter. JJJ Advisors Inc. acquired a new stake in shares of Zoetis in the 2nd quarter worth $25,000. Private Ocean LLC acquired a new stake in shares of Zoetis in the 1st quarter worth $27,000. Next Capital Management LLC increased its stake in shares of Zoetis by 156.5% in the 2nd quarter. Next Capital Management LLC now owns 295 shares of the company’s stock worth $33,000 after acquiring an additional 180 shares during the last quarter. Finally, Destination Wealth Management increased its stake in shares of Zoetis by 217.9% in the 2nd quarter. Destination Wealth Management now owns 337 shares of the company’s stock worth $38,000 after acquiring an additional 231 shares during the last quarter. Hedge funds and other institutional investors own 90.42% of the company’s stock.

In related news, Director Willie M. Reed sold 1,900 shares of the firm’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the transaction, the director now directly owns 2,816 shares in the company, valued at approximately $311,393.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total value of $562,293.37. Following the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at $4,181,608.10. The disclosure for this sale can be found here. Insiders have sold a total of 43,432 shares of company stock valued at $5,083,246 over the last three months. Corporate insiders own 0.29% of the company’s stock.

A number of brokerages have issued reports on ZTS. BMO Capital Markets raised their target price on Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. Barclays raised their target price on Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 target price (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Bank of America downgraded Zoetis from a “buy” rating to a “neutral” rating and raised their target price for the stock from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Finally, Craig Hallum raised their target price on Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $115.13.

Shares of NYSE:ZTS traded down $1.75 during midday trading on Thursday, reaching $125.89. 31,754 shares of the company’s stock were exchanged, compared to its average volume of 1,904,989. The firm’s 50 day simple moving average is $117.83 and its two-hundred day simple moving average is $105.05. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. The stock has a market cap of $60.93 billion, a price-to-earnings ratio of 40.28, a P/E/G ratio of 3.20 and a beta of 0.92. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $128.41.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period last year, the company earned $0.77 EPS. Equities research analysts predict that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.